Isoptin Retard

Verapamil Hydrochloride, the active ingredient in Isoptin Retard, is a calcium channel blocker presented as an extended‑release tablet for oral use. It is employed to manage high blood pressure, relieve chest pain from angina, and control certain rapid heart rhythms in adult patients.

GNH USA supplies Isoptin Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, ensuring consistent quality and regulatory compliance across markets.

Isoptin Retard, a non‑dihydropyridine calcium channel blocker, is used in cardiovascular conditions that involve elevated blood pressure or abnormal heart rhythms.

Hypertension: lowers systemic vascular resistance to reduce blood pressure. Angina pectoris: decreases myocardial oxygen demand and eases chest pain. Supraventricular tachyarrhythmias: slows AV‑node conduction to control heart rate. Atrial fibrillation (rate control): maintains ventricular response within target range.

Like all medications, Isoptin Retard may cause adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Constipation: mild difficulty passing stool. - Dizziness: light‑headedness, especially on standing. - Headache: transient cranial discomfort. - Flushing: warmth and redness of the skin.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate. - Heart block: impaired AV‑node conduction. - Severe hypotension: marked drop in blood pressure.

Before initiating therapy, clinicians should consider several safety measures.

Monitor cardiac function: assess heart rate and ECG prior to treatment. Adjust dose in hepatic impairment: reduce dosage in patients with liver dysfunction. Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. Use caution in heart failure: evaluate left‑ventricular function before use. Pregnancy and lactation: safety not established; weigh risks and benefits. Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Verapamil may interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Beta‑blockers: combined effect may cause excessive bradycardia. - Digoxin: increased risk of digitalis toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): elevate verapamil plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure lowering. - Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy.